Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 16, 2004
- Impact of NHI Price Revision in April Should Be Greater than 4.2% for Some Companies: Mr Yashiro
February 16, 2004
- JPA Warns Against Over-promotion of Self-medication for Economic Reasons
February 16, 2004
- Pfizer Aiming to Make Norvasc Top Japan Drug
February 16, 2004
- EPS, Soiken Form Alliance in Clinical Development of Specified Health Food
February 16, 2004
- NBI Focuses on Neurology, Immunology, CV, Cancer
February 16, 2004
- OTC NEWS IN BRIEF
February 16, 2004
- BUSINESS NEWS IN BRIEF
February 16, 2004
- 1st 3 Qtrs Business Results
February 16, 2004
- WEBSITE NEWS
February 16, 2004
- Over 50% of Patients Think Bungyo Should Be Promoted: Survey
February 16, 2004
- 1st 3 Qtrs Business Results -1-
February 16, 2004
- DIAGNOSTIC NEWS IN BRIEF
February 16, 2004
- 1st 3 Qtrs Business Results -2-
February 16, 2004
- MEDICAL DEVICE NEWS IN BRIEF
February 16, 2004
- New Drug Organization to Start with 9 Departments Responsible for Application Review
February 16, 2004
- WORLD NEWS IN BRIEF
February 16, 2004
- Chuikyo Talks Break Down on Expanding DPC System to Private Hospitals
February 16, 2004
- AnGes MG, Gene Design to Codevelop 3rd-Generation Decoy Products
February 16, 2004
- Caution Urged Again over Long-term Use of Estrogen: Safety Info No. 197
February 9, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…